Physician profile
Oscar Quezada
NPI 1770670945
$1,345.12
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $739 · 2020: $245 · 2021: $160 · 2022: $201.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $379.15 | 2019-2022 | |
| Therapeuticsmd, INC. | $174.78 | 2019-2020 | |
| Abbvie INC. | $156.39 | 2019-2020 | |
| Allergan, INC. | $137.61 | 2019-2020 | |
| Daiichi Sankyo INC. | $133.84 | 2019-2020 | |
| Astellas Pharma US INC | $96.91 | 2019-2020 | |
| Applied Medical Resources Corporation | $65.33 | 2021 | |
| Aspira Women'S Health INC | $55.03 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $46.54 | 2019-2020 | |
| Avanos Medical | $39.71 | 2019 | |
| Exeltis, USA INC. | $19.30 | 2020 | |
| Pfizer INC. | $15.19 | 2019 | |
| Coopersurgical, INC. | $14.07 | 2020 | |
| Amag Pharmaceuticals, INC. | $11.27 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Oscar Quezada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.